P/E ratio for AVEO Oncology (AVEO)

P/E ratio history for AVEO Oncology from 2010 to 2022

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Biogen BIIB	7.93	-144.43%	🇺🇸 USA
Regeneron Pharmaceuticals REGN	18.8	-205.20%	🇺🇸 USA
Merrimack Pharmaceuticals MACK	-138	670.25%	🇺🇸 USA
Bristol-Myers Squibb BMY	14.4	-180.87%	🇺🇸 USA
Eli Lilly LLY	141	-891.90%	🇺🇸 USA
Amgen AMGN	18.6	-204.24%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.